← Scroll for more →
Inhibrx Biosciences, Inc. (INBX)
Biological Products, (No Diagnostic Substances)
Latest Price
$100.08
TTM P/E
--
Normalized P/E
3.92
Div Yield
--
Book Value
0.55
P/B Ratio
182.10
Institutional Ownership
99.3% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Morgan Stanley | 1.31M | $123.0M | 8.89% | +45.0K | 2026-06-30 |
| Perceptive Advisors LLC | 1.30M | $122.0M | 8.82% | -144.9K | 2026-06-30 |
| Sanofi | 1.16M | $109.0M | 7.87% | -- | 2026-06-30 |
| Viking Global Investors LP | 1.12M | $106.0M | 7.64% | -313.8K | 2026-06-30 |
| HighTower Advisors, LLC | 870.6K | $82.0M | 5.92% | +351 | 2026-06-30 |
| Bank of America Corp | 841.1K | $79.0M | 5.72% | +808.5K | 2026-06-30 |
| BlackRock, Inc. | 826.0K | $78.0M | 5.62% | +27.1K | 2026-06-30 |
| Schonfeld Strategic Advisors LLC | 697.6K | $66.0M | 4.74% | +442.8K | 2026-06-30 |
| State Street Corp | 640.5K | $60.0M | 4.35% | +89.6K | 2026-06-30 |
| Vanguard Capital Management LLC | 492.5K | $46.0M | 3.35% | +6.1K | 2026-06-30 |